Psychedelic-Assisted Therapy

In this episode, I explore the growing scientific interest in psychedelic-assisted therapy as a potential treatment for substance use disorders, particularly opioid addiction. I trace the historical roots of psychedelic therapy, review emerging evidence on substances like lysergic acid diethylamide (LSD), ketamine, psilocybin, and ibogaine, and highlight the challenges of translating promising findings into safe, regulated clinical practice. Download the one-pager (PDF). This project was supported by Grant [5PBJA-22-AG-00031-MUMU] awarded by the Bureau of Justice Assistance. The Bureau of Justice Assistance is a component of the Office of Justice Programs, which also includes the Bureau of Justice Statistics, the National Institute of Justice, the Office of Juvenile Justice and Delinquency Prevention, the Office for Victims of Crime, and Office of Sex Offender Sentencing, Monitoring, Apprehending, Registering, and Tracking. Points of view or opinions in this podcast are those of the host and the research team and do not necessarily represent the official position or policies of the U.S. Department of Justice.